Created at	Source	Raw Value	Validated value
May 15, 2021, 12:32 a.m.	usa	Geometric mean ratio of lyophilized BNT162b2 in single-dose vials is noninferior to frozen-liquid BNT162b2 in multi-dose vials in participants without evidence of SARS-CoV-2 infection;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events;Percentage of participants reporting systemic events	Geometric mean ratio of lyophilized BNT162b2 in single-dose vials is noninferior to frozen-liquid BNT162b2 in multi-dose vials in participants without evidence of SARS-CoV-2 infection;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events;Percentage of participants reporting systemic events
March 27, 2021, 12:31 a.m.	usa	Geometric mean ratio from lyophilized BNT162b2 in MDVs is noninferior to frozen-liquid BNT162b2 in MDVs in participants without evidence of SARS-CoV-2 infection;Geometric mean ratio from lyophilized BNT162b2 in single-dose vials is noninferior to frozen-liquid BNT162b2 in MDVs in participants without evidence of SARS-CoV-2 infection;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events;Percentage of participants reporting systemic events	Geometric mean ratio from lyophilized BNT162b2 in MDVs is noninferior to frozen-liquid BNT162b2 in MDVs in participants without evidence of SARS-CoV-2 infection;Geometric mean ratio from lyophilized BNT162b2 in single-dose vials is noninferior to frozen-liquid BNT162b2 in MDVs in participants without evidence of SARS-CoV-2 infection;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events;Percentage of participants reporting systemic events